Adipokines in RA ⚡️Highest Quartile Adiponectin associated w/ ⬆️ all-cause mortality HR 1.46 ⬆️ CV mortality HR 1.85 ⚡️Highest Quartile Leptine ⬆️ 25% all-cause mortality #ACR21 #Abst1645 @RheumNow https://t.co/O1NAbfMvif https://t.co/VVdgZHP1j5

• https://bit.ly/3D05NNx

No clear excess risk for offspring exposed in-utero to, VED or TNFi's. UST showed infection signal BUT w/ wide CIs. We need more research re: biologics and placental transmission potential/subsequent risks. Abs 1713 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/W3K5uDyHlC

• Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedo…

b/tsDMARDs + tumor response in rheum irAEs Excellent point by @CCalabreseDO @LCalabreseDO: - despite progression in 5/10, DMARD contribution uncertain (bad cancer) - without DMARD, ICI would have had to stop crucial question, prospective study needed #ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH

The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abs 1774 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/huNTY3IdRf https://t.co/3aW64pb9UW

• Blood-based Immune Profiling Combined with Machine Learning Discriminates Psori…

Great case where the #COVIDvaccine was blamed, but he had a diet of doughnuts, steak&cheese sandwiches w/snack cakes, and popsicles. #ThievesMarket #ACR21 @rheumnow https://t.co/J78Nw5NhKs

The #ACR21 Playbook This playbook is designed to help you navigate a truly big meeting (with >2000 presentations and over 15,000 attendees from over 100+ countries). What follows is based on experience and the acquired insights our peers. https://t.co/GlDOnVfHsc https://t.co/RQlM2fjCzY

• https://bit.ly/3CVxfvJ

Autoantibodies are underrated in rheumatic irAEs (?B cells in general), but probably not your usual. If Ab are of interest, suspect we're going to have to look at non-classical ones Elegant from @NilashaGhosh @MPostow @got_rheum @lovetolearn27 #ACR21 ABST1520 ABST1521 @RheumNow https://t.co/tLSJOZw1YG

Great conversation with @BayviewMedicine @jhrheumatology alum Dr. Jason Liebowitz and Professor Janet Zeide on "Gift of Gab"- communications skills for the rheumatologist at #ACR21! @Rheumnow https://t.co/O1u3X8urag

Abst1783 #ACR21 #ACRBest @RheumNow Canadian study reports promising trends on hospitalizations for serious infections in PsA: 2012 – 2017 statist signif ⬇️ in discharges for sepsis, skin & soft tissue infect & UTI (p < 0.001 for all). no statistical difference in the trend of PNA https://t.co/lqtCzUFPAW

We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2

Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802 https://t.co/QvyayelBYU https://t.co/50dNQm30vf

• https://bit.ly/3bWiQmZ

How do RA pts go with ICI cancer therapy? @VUMCRheum audit reflects overall prev experience: - approx 50% flare (?some reflect DMARD W/H) - flares overwhelmingly managable - few (1/19 here) cease ICI due to RA flare RA pts deserve best cancer Rx too!! #ACR21 ABST1523 @RheumNow

Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416